%PDF-1.4
%
50 0 obj
<>
endobj
46 0 obj
[/CalGray<>]
endobj
47 0 obj
[/CalRGB<>]
endobj
101 0 obj
<>stream
Acrobat PDFWriter 4.05 for Power Macintosh
2003-05-30T11:45:12Z
2024-03-29T02:59:52-07:00
2024-03-29T02:59:52-07:00
QuarkXPress™ 4.11
application/pdf
Heather
uuid:d8a76e3d-1dd1-11b2-0a00-c20927fd5800
uuid:d8a76e3f-1dd1-11b2-0a00-6a0000000000
endstream
endobj
45 0 obj
<>
endobj
51 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Type/Page>>
endobj
33 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/Type/Page>>
endobj
111 0 obj
[113 0 R]
endobj
112 0 obj
<>stream
1 g
419.25 750.75 137 10.25 re
f
0 g
53.25 54.25 504 1 re
f
BT
/TT0 8 Tf
0.2 Tw 423.727 36.75 Td
(The Journal of Rheumatology 2003; 30:7)Tj
0 Tw -370.352 -0.25 Td
(1512)Tj
ET
1 g
108.25 48.75 397 11.25 re
f
108.75 49.25 396 10.25 re
f
q
0 g
397 0 0 11.25 108.25 48.75 cm
/Im0 Do
Q
BT
0 g
/TT1 8 Tf
60.375 382.25 Td
[(3.)-875 (Allison A, Eugui E. Purine metabolism and immunosuppressive)]TJ
13.494 -10 Td
[(effects of mycophenolate mofetil \(MMF\). Clin )-85.25 (T)0.125 (ransplant)]TJ
-0.097 -10 Td
(1996;10:77-84.)Tj
-13.391 -10 Td
(4.)Tj
0.2 Tw 13 0 Td
(European Mycophenolate Mofetil Cooperative Study Group.)Tj
0.371 -10 Td
(Placebo-controlled study of mycophenolate mofetil combined with)Tj
0.118 -10 Td
(cyclosporin and corticosteroids for prevention of acute rejection.)Tj
0 Tw -0.065 -10 Td
(Lancet 1995;345:1321-5. )Tj
-13.479 -10 Td
[(5.)-875 (The )-24.75 (T)62.625 (ricontinental Mycophenolate Mofetil Renal )-97 (T)31.375 (ransplantation)]TJ
13.63 -10 Td
[(Study Group. )12.375 (A)]TJ
0.2 Tw 52.54 0 Td
(blinded, randomized clinical trial of mycophenolate)Tj
-52.531 -10 Td
(mofetil for the prevention of acute rejection in cadaveric renal)Tj
0 Tw -0.157 -10 Td
[(transplantation. )7.375 (T)31.375 (ransplantation 1996;61:1029-37.)]TJ
-13.49 -10 Td
[(6.)-875 (Sollinger HW. Mycophenolate mofetil for the prevention of acute)]TJ
0.2 Tw 13.479 -10 Td
(rejection in primary cadaveric renal allograft recipients. U.S. Renal)Tj
0.092 -10 Td
[(T)62.625 (ransplant Mycophenolate Mofetil Study Group. )1.625 (T)]TJ
0 Tw 164.219 0 Td
(ransplantation)Tj
-164.18 -10 Td
(1995;60:225-32.)Tj
-13.641 -9.75 Td
[(7.)-875 (Chan TM, Li FK, )-68.625 (T)]TJ
0.2 Tw 76.16 0 Td
(ang CS, et al. Efficacy of mycophenolate)Tj
0.138 Tw -62.542 -9.75 Td
(mofetil in patients with diffuse proliferative lupus nephritis. Hong)Tj
0.2 Tw -0.107 -9.75 Td
(Kong-Guangzhou Nephrology Study Group. N Engl J Med)Tj
0 Tw -0.037 -10 Td
(2000;343:1156-62.)Tj
-13.391 -9.75 Td
(8.)Tj
0.2 Tw 13 0 Td
(Murray LM. Physicians desk reference. 55th ed. Montvale, New)Tj
0 Tw 0.514 -9.75 Td
(Jersey: Medical Economics Company, Inc; 2001.)Tj
-13.48 -9.75 Td
[(9.)-875 (T)]TJ
0.117 Tw 17.137 0 Td
(an EM, Cohen AS, Fries, JF, et al. The 1982 revised criteria for)Tj
0 Tw -3.561 -9.75 Td
(the classification of systemic lupus erythematosus. Arthritis Rheum)Tj
-0.194 -10 Td
(1982;25:1271-7. )Tj
-17.441 -9.75 Td
[(10.)-875 (Hochberg, MC. Updating the American College of Rheumatology)]TJ
0.2 Tw 17.631 -9.75 Td
(revised criteria for the classification of systemic lupus )Tj
0 Tw -0.095 -9.75 Td
(erythematosus. Arthritis Rheum 1997;40:1725.)Tj
246.725 257.5 Td
[(1)31.25 (1.)]TJ
0.175 Tw 16.75 0 Td
(Gladman D, Ginzler E, Goldsmith C, et al. The development and)Tj
0.2 Tw 0.449 -9.75 Td
(initial validation of the Systemic Lupus International Collaborating)Tj
0.189 -9.75 Td
(Clinics/American College of Rheumatology damage index for)Tj
0 Tw -0.241 -9.75 Td
(systemic lupus erythematosus. Arthritis Rheum 1996;39:363-76.)Tj
-17.379 -10 Td
(12.)Tj
0.2 Tw 17 0 Td
(Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the)Tj
0 Tw 0.535 -10 Td
[(SLEDAI: )68.75 (A)-218.875 (disease activity index for lupus patients. Arthritis)]TJ
-0.135 -10 Td
(Rheum 1992;35:630-40.)Tj
-17.331 -10 Td
(13.)Tj
0.125 Tw 17 0 Td
(Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help )Tj
0.2 Tw 0.445 -10 Td
(optimizing mycophenolate mofetil dosing in kidney transplant)Tj
0 Tw -0.03 -10 Td
[(patients. Clin )-17.75 (T)31.375 (ransplant 2001;15:402-9.)]TJ
-17.415 -10 Td
[(14.)-875 (Fulton B. Markham A. Mycophenolate mofetil. )-23.125 (A)-218.875 (review of its)]TJ
0.2 Tw 17.342 -10 Td
(pharmacodynamic and pharmacokinetic properties and clinical )Tj
-0.023 -10 Td
(efficacy in renal transplantation. Drugs 1996;51:278-98. )Tj
0 Tw -17.378 -10 Td
[(15.)-875 (Bullingham RES, Nicholls AJ, Kamm BR. Clinical )]TJ
17.373 -10 Td
(pharmacokinetics of mycophenolate mofetil. Clinical)Tj
0.191 -10 Td
(Pharmacokinet 1998;34:429-55. )Tj
-17.506 -10 Td
[(16.)-875 (W)]TJ
0.2 Tw 24.301 0 Td
(iwattanawongsa K. Heinzen EL. Kemp DC. Dupuis RE, Smith)Tj
-6.791 -10 Td
(PC. Determination of mycophenolic acid and its phenol)Tj
-0.166 -10 Td
(glucuronide metabolite in human plasma and urine by )Tj
0 Tw -0.029 -10 Td
(high-performance liquid chromatography. J Chromatogr B Biomed)Tj
0.04 -10 Td
(Sci Appl 2001;763:35-45.)Tj
-17.518 -10 Td
[(17.)-875 (Beal JL. Jones CE. )-99.5 (T)62.625 (aylor PJ. )-18.75 (T)62.625 (ett SE. Evaluation of an)]TJ
0.2 Tw 17.637 -10 Td
(immunoassay \(EMIT\) for mycophenolic acid in plasma from renal)Tj
-0.13 -10 Td
(transplant recipients compared with a high-performance liquid)Tj
0 Tw 0.13 -10 Td
[(chromatography assay)69.5 (.)-281.25 (Ther Drug Monit 1998;20:685-90. )]TJ
ET
q
30 31 552 730 re
W n
1 g
407.25 745.75 150 25 re
f
407.25 745.75 150 15.25 re
f
BT
0 g
/TT0 8 Tf
127.616 715.25 Td
[(T)93.625 (able 6. )]TJ
/TT1 8 Tf
-0.129 Tw 28.964 0 Td
(Clinical course variables among patients with renal disease at baseline,\
no renal disease at baseline, and)Tj
0.2 Tw -29.026 -10 Td
(all patients across the 3 study time points [data expressed as mean \(SD\
\)].)Tj
0.146 -20 Td
(V)Tj
0 Tw 4.777 0 Td
(ariable)Tj
69.262 0 Td
(All Patients)Tj
0.2 Tw 51.505 0 Td
[(Baseline Renal Disease \(n = 26\))-1561.25 (No Baseline Renal Disease \(n = 28\) )]TJ
0 Tw -125.721 -20 Td
(SLEDAI score)Tj
6.02 -10 Td
(Baseline)Tj
73.297 0 Td
(5.0 \(4.3\))Tj
84.528 0 Td
(4.6 \(3.7\))Tj
122.528 0 Td
(5.3 \(4.8\))Tj
-280.222 -10 Td
(3 mos)Tj
73.286 0 Td
(3.5 \(3.7\))Tj
82.528 0 Td
(2.9 \(3.4\)*)Tj
120.278 0 Td
(4.4 \(4.0\)**)Tj
-276.222 -10 Td
(Final)Tj
71.445 0 Td
(2.7 \(3.8\)*)Tj
82.278 0 Td
(2.5 \(4.5\)**)Tj
124.528 0 Td
(2.9 \(3.0\)*)Tj
-284.222 -10 Td
(Prednisone, mg)Tj
5.973 -10 Td
(Baseline)Tj
69.297 0 Td
(20.1 \(15.4\))Tj
84.528 0 Td
(20.4 \(15.3\))Tj
122.528 0 Td
(19.9 \(15.7\))Tj
-276.222 -10 Td
(3 mos)Tj
69.286 0 Td
(12.6 \(8.8\)*)Tj
80.528 0 Td
(14.0 \(10.4\)**)Tj
126.278 0 Td
[(1)31.25 (1.1 \(6.5\)*)]TJ
-276.222 -10 Td
(Final)Tj
67.445 0 Td
(12.2 \(11.5\)*)Tj
82.528 0 Td
(12.1 \(11.8\)**)Tj
122.278 0 Td
(12.2 \(11.5\)**)Tj
-278.222 -10 Td
(Serum creatinine, mg/dl)Tj
5.99 -10 Td
(Baseline)Tj
73.297 0 Td
(1.3 \(1.0\))Tj
84.528 0 Td
(1.5 \(1.3\))Tj
122.528 0 Td
(1.0 \(0.2\))Tj
-280.222 -10 Td
(3 mos)Tj
73.286 0 Td
(1.2 \(0.8\))Tj
84.278 0 Td
(1.4 \(1.0\))Tj
122.528 0 Td
(1.0 \(0.2\))Tj
-280.222 -10 Td
(Final)Tj
73.195 0 Td
(1.5 \(1.6\))Tj
84.528 0 Td
(1.8 \(2.1\))Tj
122.528 0 Td
(1.0 \(0.3\))Tj
-286.222 -10 Td
(C3, mg/dl)Tj
5.954 -10 Td
(Baseline)Tj
69.297 0 Td
(98.3 \(24.2\))Tj
84.528 0 Td
(96.8 \(25.1\))Tj
122.528 0 Td
(99.8 \(23.8\))Tj
-276.222 -10 Td
(3 mos)Tj
67.286 0 Td
(100.2 \(28.2\))Tj
86.278 0 Td
(97.4 \(33.4\))Tj
120.528 0 Td
(104.3 \(18.5\))Tj
-274.222 -10 Td
(Final)Tj
67.195 0 Td
(104.3 \(26.2\))Tj
84.528 0 Td
(101.7 \(23.7\))Tj
118.528 0 Td
(107.5 \(29.3\)**)Tj
-276.222 -10 Td
(C4, mg/dl)Tj
5.954 -10 Td
(Baseline)Tj
71.297 0 Td
(21.2 \(8.9\))Tj
82.528 0 Td
(23.5 \(10.4\))Tj
124.528 0 Td
(19.0 \(6.6\))Tj
-278.222 -10 Td
(3 mos)Tj
69.286 0 Td
(25.4 \(22.4\))Tj
84.528 0 Td
(28.9 \(28.3\))Tj
124.278 0 Td
(20.1 \(5.3\))Tj
-278.222 -10 Td
(Final)Tj
71.445 0 Td
(20.2 \(8.5\))Tj
84.278 0 Td
(21.0 \(9.1\))Tj
122.528 0 Td
(19.2 \(7.8\))Tj
-284.222 -10 Td
(Anti-dsDNA, log titer)Tj
6.088 -10 Td
(Baseline)Tj
73.297 0 Td
(2.9 \(1.5\))Tj
84.528 0 Td
(3.0 \(1.5\))Tj
122.278 0 Td
(2.8 \(1.6\))Tj
-280.222 -10 Td
(3 mos)Tj
73.286 0 Td
(2.9 \(1.6\))Tj
84.528 0 Td
(3.1 \(1.6\))Tj
122.528 0 Td
(2.7 \(1.6\))Tj
-280.222 -10 Td
(Final)Tj
73.195 0 Td
(2.8 \(1.7\))Tj
84.528 0 Td
(3.1 \(1.8\))Tj
122.528 0 Td
(2.4 \(1.4\))Tj
0.039 Tc -286.222 -20 Td
(All 3-month and final values compared to baseline using one-way )Tj
0 Tc -2.03999 Tw 215.582 0 Td
[(A N O V)155.625 (A)]TJ
0.056 Tc 0 Tw 29.766 0 Td
(for repeated measures. * p )Tj
/TT2 8 Tf
88.184 0 Td
(\243)Tj
/TT1 8 Tf
0 Tc 4.141 0 Td
( 0.01, )Tj
-337.75 -10 Td
(** p )Tj
/TT2 8 Tf
16.25 0 Td
(\243)Tj
/TT1 8 Tf
4.141 0 Td
( 0.05, all other comparisons p = NS.)Tj
ET
126.25 698.5 362 0.5 re
f
125.25 679.5 360 0.5 re
f
125.25 428.5 360 0.5 re
f
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/T1_0 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
40 0 obj
<>/Filter/CCITTFaxDecode/Height 45/ImageMask true/Length 24/Name/I7/Subtype/Image/Type/XObject/Width 1588>>stream
ˁh?
endstream
endobj
81 0 obj
<>
endobj
104 0 obj
<>
endobj
54 0 obj
<>
endobj
56 0 obj
<>
endobj
43 0 obj
<>
endobj
113 0 obj
<>
endobj
114 0 obj
<>
endobj
109 0 obj
[115 0 R]
endobj
110 0 obj
<>stream
BT
/TT0 10 Tf
1.746 Tw 53.42 183 Td
(for prospective studies and may be limited when applied)Tj
0 Tw 0.017 -12 Td
[(retrospectively)76.1 (.)]TJ
0.974 Tw 11.919 -12 Td
(Our results show that a wide range of MMF doses was)Tj
0.394 Tw -11.958 -12 Td
(well tolerated and associated with a good clinical response.)Tj
1.756 Tw 0.02 -12 Td
(Hence, drug dosing should be individualized and clinical)Tj
0.186 Tw 0.01 -12 Td
(trial design should account for variability of drug tolerance.)Tj
2.136 Tw 0.022 -12 Td
[(Cost-effective techniques to measure levels of mycophe)3.3 (-)]TJ
0.593 Tw -0.047 -12 Td
(nolic acid or its phenol glucuronide metabolite in blood by)Tj
0.502 Tw 0.007 -12 Td
(a single determination)Tj
/TT0 6.25 Tf
0 Tw 1.04 0 0 1.04 143.025 90.25 Tm
(16,17)Tj
/TT0 10 Tf
0.502 Tw 1 0 0 1 160.837 87 Tm
[(may prove advantageous in clin)1.8 (-)]TJ
0.25 Tw -107.48 -12 Td
(ical care or future research trials.)Tj
/TT1 10 Tf
0 Tw 264.087 108 Td
(ACKNOWLEDGMENT)Tj
/TT0 8 Tf
-0.188 -10 Td
(The authors would like to thank Drs. Barbara Adams, David Fox, Kathleen)Tj
0.746 Tw 0.215 -10 Td
(Lake, and Lawrence Holzman for their critical reading of the manuscript)Tj
0 Tw 0.022 -10 Td
(and helpful advice.)Tj
/TT1 10 Tf
-0.014 -17 Td
(REFERENCES)Tj
/TT0 8 Tf
6.986 -10 Td
[(1.)-875 (McCune WJ, Riskalla MM. Immunosuppressive drug therapy. In:)]TJ
13.287 -10 Td
(W)Tj
0.492 Tw 6.801 0 Td
(allace DJ, Hahn B, editors. Dubois\325lupus erythematosus.)Tj
0 Tw -6.749 -10 Td
[(Philadelphia: Lippincott )-47.875 (W)62.625 (illiams and )-17.75 (W)31.375 (ilkins; 2001:1195-217.)]TJ
-13.386 -10 Td
(2.)Tj
0.125 Tw 13 0 Td
(Allison A, Eugui E. The design and development of an )Tj
0.2 Tw 0.492 -10 Td
(immunosuppressive drug, mycophenolate mofetil. Springer Semin)Tj
0 Tw -0.117 -10 Td
(Immunopathol 1993;14:353-80.)Tj
ET
1 g
419.25 750.75 137 10.25 re
f
q
0 g
299.5 0 0 233.25 155.25 487.5 cm
/Im0 Do
Q
BT
0 g
/TT2 8 Tf
155.456 479.25 Td
(Figure 1.)Tj
/TT0 8 Tf
0.314 Tw 31.838 0 Td
(Number of patients receiving each MMF dose at final followup, stratified\
by those)Tj
0 Tw -31.824 -10 Td
[(who continued MMF and those who discontinued MMF)-22.25 (.)-250 (The 4 patients who discontinued for)]TJ
1.769 Tw -0.073 -10 Td
(non-medication related reasons \(pregnancy and administrative\) were cla\
ssified as having)Tj
0 Tw 0.031 -10 Td
[(continued MMF)68.875 (.)]TJ
ET
q
0 g
299.5 0 0 189 154.25 242.75 cm
/Im1 Do
Q
BT
/TT2 8 Tf
155.352 231.25 Td
(Figure 2.)Tj
/TT0 8 Tf
0.509 Tw 32.532 0 Td
(Kaplan-Meier estimate of proportion of patients continuing MMF as a func\
tion of)Tj
1.756 Tw -32.463 -10 Td
(time. \()Tj
/T1_0 8 Tf
0 Tw 22.639 0 Td
(l)Tj
/TT0 8 Tf
1.756 Tw 6.32 0 Td
(: censored observation, indicates final point of followup for patients c\
ontinuing)Tj
0 Tw -28.94 -10 Td
(MMF\).)Tj
ET
q
30 31 552 730 re
W n
1 g
407.25 745.75 150 25 re
f
407.25 745.75 150 15.25 re
f
0 g
53.25 54.25 504 1 re
f
BT
/TT2 8 Tf
0.2 Tw 53.78 36.75 Td
(Riskalla, et al: Mycophenolate mofetil and SLE)Tj
0 Tw 487.696 -0.25 Td
(1511)Tj
ET
1 g
108.25 48.75 397 11.25 re
f
108.75 49.25 396 10.25 re
f
q
0 g
397 0 0 11.25 108.25 48.75 cm
/Im2 Do
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/T1_1 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
28 0 obj
<>/Filter/CCITTFaxDecode/Height 974/ImageMask true/Length 5104/Name/I4/Subtype/Image/Type/XObject/Width 1250>>stream
&w
/8 QĩM~l3PBܜJ4Y
Dx<]"8rp3JuR쁁SS[\% l9px+9:_ C%2C-g0iy"W__.
p_r|
7ASA
bdlkoߧog'5qcȖB>A,G`E8aBA G0 ~l6]
OMt;~kik^=Ə,CFT99Qʎ<土8YQ?_8JNG/C^}h/_5?!8 5/~_^_/V}!88uP״'g'/M{ H""m"!lS/2P\8/(R ?_)B
P_`<2rn?d6y~'L8
H,@kUmB_A}`y>"Y{RsAB/U>A!2C a45P(]9:={O?^Kۜ.9?kЊpB/)[mzbW*U<_]BrF6+8W_ a{(" ªj<՟_P(%
sDd f?<
qrhUU
A x3a}_w!C k74sku_9Naȣ\r1kKm2(D8f:" xe6#>Z9hja9CrˡXS!< KRaZ@3
W[(< ??<2@j|7O~Z$/_i5_x A {!r# yrjޤ2C0rO?^z|}%|0c,?45mWsY4Z$"dpx)R9v@!90APx)h,Al4AsLr9*
9ßʂ(r"a°89!9P|<ȣ9+r(s*
sqy|ra{_#{
A@#Qf@1OG00yAqL| yX(}
#~#-\U |}mG_G
.]Hdhk_گ xoO [ x4B!3x/vZ\k@=GxO@32
{ᅐ6a?
??п ?+@4? xoMusPQ/_C?@w,_AHOcTR M!ԆmG]}5W" r 9͇sVW9C0~;eyNx(W
X43
,>Z3[ׯկ?́o_g/BVAe?ɗ_ ;./@XAp<@gu3@3|}-!?
wk7OUK^TKkaǿ!
9r9CEP
7
A!d?ɇ__ xe_V@2XdP9 xC8?>?W p?ZbD)E莈菗\dtG3c#CLrCrnB;r* AxP39ɏ@bx 2CmTᖪ@4_
C?C$SP?<Sd?
8)?B/P_Br `?
P
e//(_A _A|":
|A
<(%/
<R0<.2C8꿐A/(/ n?
(SE,?/
?P
P xH%W|XPPAAs0V*`xfb]̎dx]
H.wG@<3<SA!D^UB'_P H/҂@|PP
U_UU At_qU_BPP_Ap|/k
A~(*¯B(.
xn?.
haAxxP@@r
P^?,(/=APzP(^<(_/ҙ
B@
P)x(_ (_A|(_ /(_(\/P_BpPpp~PP
b`yؘ*$pBP5$)P_aBJ.(_pP\(KP
*
/
/_uAh(^IP@B-BB.
H- _
BP\(_B.
~./A K%h(_
q@/P|(_
(/BUP*WRH/[qJ|*_
P_pPࠗ q|/P/* k҅_TH B
P5
/.:P/(XApP
$(%=z P\$r
cAp(U
aB(.BP\$P_(\/
U]AP\$ H(]_y
P.'
BL-߭Kto~
Y/"8#"?&G_Ɵd0 dCdc_߯GwH@4@C@>?2G? x*x^#/<4dOFr|G#?#_>"dOOM5M4M4TTiiizkiM=;ӽ
`!os|*7Q0!7Q7oymѹ?O~IoIn'I}to\S}{W{t{3{ǐ<5m^p}ff3T35*Z++
WJ_,9sp/~/]L'% (O<4X {tͯ^U#ͯ#/z<2u^k]ZW{+^IWWտJ[__Z+To]t#S{hlq$bbSq1N54:iݦ
i
4Ӱh5; K`
C$d28
C%3LQ iќ??O_
ENR'd%A}]@a==O4J-[_Y-ӵ0=}מ~_@nmga$={qQ_l~_CT[g]{x_+o+
ſiXv~W/j/xkO_oa0_.@'`ˁgx1Hd[/IuoY`Qa/@&@F!
endstream
endobj
30 0 obj
<>/Filter/CCITTFaxDecode/Height 790/ImageMask true/Length 2846/Name/I5/Subtype/Image/Type/XObject/Width 1250>>stream
&w
/C"d
(ȣhԎ."s03c.Dt^#:.^Z`
FGy_ M9Pr+r/O u
Bgx@2s%BTq:IfMl} mICi
dwar"=X+
8! V5 xj 41= _C__P |/`tNX N?zg3C 0B<@<܁@
q_Ha?<_<09?k
C,!3:2 =/W A{_C$X
?'O '"a(r"a? BA3'~/Ng
֕5.vGd*#,U>AC@ο@|*GU Vm/_?ooN\2BqNx09Aa[~KU&FDC&_#@K<"g?"_I|4s@\d^C MT/_Blϙ?2P*r]
v]?|&P0䄿&gD?(3Sm!
505M5I>rD8c
|*o>eݰԔbUƭkkXViijDEa?~D«!rOR4AjK:4@T3-~iM0 k9g'6o9g'OON7W_U{k'3Ӱ
`f
S`
303dl _amaG
S_a;4azO:x_a0!?>Aqo_xAO50 G~?
TԁyzүƿW_%AJH&
\
n>C"ߑG?Gx1eߐ`@c߇_ sG:X;1_0BBq<}kq!z m f?b>^9#گk/
_???y`2@n?_ O`V8Du:|GY~?OA
?ϧ
,6_r0ᯏjaBG@
A $.y)K_)A<_ka~?6A}_!d4Y d]>xaNFPud1,7QUi{ %A[hE~A~CF{&d"@!b>ᅐ:8\*=//~A|A^kK|(6㏐A@7 K!}
cXa~?A>?
,G fdG,4!??>@>?@
`k?5 l5%a?L}jJ@c6d f
C! @ x+#_@̃'2S'66 YvCX?[^Ѵ:e:#3HTGC0U bdx!9
!sV9)9C4ArC Y/2*+ڮp50f!c9O!(C ȾC $hC!!~Kdt
Hd*A@`]trT洚9=-[Iãa)0T`2!Mգ@z4Fa+ 8 xf#ȳ_~>
B`~t'd nV;"NTC ḾPBD2(U!Q D *)QXjPfYi uq
j?@r.}OQzzGxק灿e?_h^^P><
-t|G!>? A<